Measurement of serum soluble CD4 levels in patients with external anogenital warts before and after intralesional injection of tuberculin purified protein derivative

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202006534973105

Enrollment

Registered

2020-06-17

Start date

2018-09-20

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

Patients with anogenital warts afmeasurment of sCD4 level after PPD injection

PPD injection

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: male patients complaining of external anogenital warts more than 18 years of age.

Exclusion criteria

Exclusion criteria: Exclusion Criteria included immuno-compromised patients (HIV, chronic debilitating diseases or malignancy); patients with hemolytic blood diseases patients, patients with active tuberculosis and patient received any other modality for treatment for genital warts during study or in the last 3 months.

Design outcomes

Primary

Measure	Time frame
Mean level of serum soluble CD4 was significantly higher after than before PPD injection.	—

Secondary

Measure	Time frame
Serum sCD4 levels were significantly correlated to clinical response rates as the higher the level of serum sCD4 the more wart recovery.	—

Countries

Egypt

Contacts

Public ContactMohamed Azab

lectrurer

Dr.Mohamed_azab@yahoo.com002001224560152

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026